Published in N Engl J Med on January 15, 2009
Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med (2008) 7.25
Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study. Lancet (2012) 6.29
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) (2002) 6.03
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA (2005) 3.89
Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA (2004) 3.88
Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation (2006) 3.69
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation (2004) 2.56
Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet (2008) 2.53
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension (2012) 2.42
Exercise capacity and mortality in black and white men. Circulation (2008) 2.17
Left ventricular hypertrophy as a determinant of renal outcome in patients with high cardiovascular risk. J Hypertens (2010) 2.14
A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol (2006) 2.13
Effects of continuous positive airway pressure on blood pressure in hypertensive patients with obstructive sleep apnea: a 3-year follow-up. J Hypertens (2013) 2.03
Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J (2013) 1.77
Consequences of adrenal venous sampling in primary hyperaldosteronism and predictors of unilateral adrenal disease. J Am Coll Surg (2010) 1.70
Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertens (2002) 1.69
Pulse pressure/stroke index and left ventricular geometry and function: the LIFE Study. J Hypertens (2003) 1.69
Left ventricular hypertrophy versus chronic kidney disease as predictors of cardiovascular events in hypertension: a Greek 6-year-follow-up study. J Hypertens (2009) 1.62
Exercise capacity and mortality in older men: a 20-year follow-up study. Circulation (2010) 1.54
Tissue factor-thrombin signaling enhances the fibrotic activity of myofibroblasts in systemic sclerosis through up-regulation of endothelin receptor A. Arthritis Rheum (2011) 1.46
Left atrial systolic force in hypertensive patients with left ventricular hypertrophy: the LIFE study. J Hypertens (2008) 1.44
Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood (2010) 1.44
Masked hypertension and atherogenesis: the impact of apelin and relaxin plasma levels. J Clin Hypertens (Greenwich) (2013) 1.44
Aspirin under fire: aspirin use in the primary prevention of coronary heart disease. Pharmacotherapy (2005) 1.41
Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache (2004) 1.39
Hypertension crisis. Blood Press (2010) 1.19
Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press (2007) 1.15
Baseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension (2001) 1.15
BMI-mortality paradox and fitness in African American and Caucasian men with type 2 diabetes. Diabetes Care (2012) 1.14
Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Circulation (2002) 1.13
Hyperuricemia as a risk factor for cardiovascular disease. Expert Rev Cardiovasc Ther (2014) 1.11
Platelet activation during exercise is not attenuated by inhibition of the renin-angiotensin system: the role of physical activity. J Hypertens (2013) 1.11
Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. Am J Cardiol (2005) 1.09
Hypertension treatment guidelines. J Clin Hypertens (Greenwich) (2004) 1.08
Exercise capacity and progression from prehypertension to hypertension. Hypertension (2012) 1.08
Blood pressure control among US veterans: a large multiyear analysis of blood pressure data from the Veterans Administration health data repository. Circulation (2012) 1.07
Macro and microcirculation damage and incident hypertension: predictors of progression? J Hypertens (2014) 1.07
Carotid baroreceptor stimulation as a therapeutic target in hypertension and other cardiovascular conditions. Expert Opin Ther Targets (2009) 1.05
Pathophysiology of resistant hypertension: the role of sympathetic nervous system. Int J Hypertens (2011) 1.03
Renal sympathetic denervation and systemic hypertension. Am J Cardiol (2010) 1.03
Sexual dysfunction: the 'prima ballerina' of hypertension-related quality-of-life complications. J Hypertens (2008) 1.03
Analysis of T-wave morphology from the 12-lead electrocardiogram for prediction of long-term prognosis in male US veterans. Circulation (2002) 1.01
Masked hypertension in untreated and treated patients with diabetes mellitus: attractive but questionable interpretations. Hypertension (2013) 0.96
Gender differences in hypertension: myths and reality. Curr Hypertens Rep (2013) 0.95
The Study on COgnition and Prognosis in the Elderly (SCOPE) - major CV events and stroke in subgroups of patients. Blood Press (2005) 0.95
Albuminuria and cognitive decline in people with diabetes and normal renal function. Clin J Am Soc Nephrol (2013) 0.95
Body mass index, exercise capacity, and mortality risk in male veterans with hypertension. Am J Hypertens (2012) 0.93
Evaluation and treatment of resistant or difficult-to-control hypertension. J Clin Hypertens (Greenwich) (2008) 0.92
Intracerebral hemorrhage as the presenting feature of concurrent pheochromocytoma and paragangliomas. J Clin Hypertens (Greenwich) (2008) 0.92
Relation of left ventricular geometry and function to aortic root dilatation in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Am J Cardiol (2002) 0.92
Cardiovascular risk in rheumatoid arthritis: pathogenesis, diagnosis, and management. J Clin Rheumatol (2012) 0.91
Antihypertensive treatment and sexual dysfunction. Curr Hypertens Rep (2012) 0.91
Diuretics, hypokalemia, and cardiac arrhythmia: a 20-year controversy. J Clin Hypertens (Greenwich) (2006) 0.91
Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med (2017) 0.91
Catheter-based renal sympathetic denervation exerts acute and chronic effects on renal hemodynamics in swine. Int J Cardiol (2012) 0.91
Renal sympathetic denervation: renal function concerns. Hypertension (2011) 0.90
Common secondary causes of resistant hypertension and rational for treatment. Int J Hypertens (2011) 0.89
Leiomyosarcoma of renal vein, initially resembling pheochromocytoma. Clin Exp Hypertens (2012) 0.88
Combined angiotensin inhibition in diabetic nephropathy. N Engl J Med (2014) 0.88
Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective. J Hypertens (2012) 0.88
Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review. Curr Med Res Opin (2013) 0.87
Exercise capacity and mortality in hypertensive men with and without additional risk factors. Hypertension (2009) 0.87
Exercise capacity and all-cause mortality in prehypertensive men. Am J Hypertens (2009) 0.86
Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy). Am J Cardiol (2004) 0.86
Beta-blockers in the management of hypertension: focus on nebivolol. Expert Rev Cardiovasc Ther (2008) 0.86
Heart rate recovery, exercise capacity, and mortality risk in male veterans. Eur J Prev Cardiol (2011) 0.86
Echocardiographic wall motion abnormalities in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE Study. Hypertension (2003) 0.85
Is it time to treat prehypertension? Hypertens Res (2008) 0.85
Surgical management of primary aldosteronism. not everything that shines is gold. Clin Exp Hypertens (2011) 0.85
Physicians' perceptions and adherence to guidelines for the management of hypertension: a national, multicentre, prospective study. Int J Hypertens (2012) 0.85
Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. J Hypertens (2002) 0.85
Metoprolol succinate combination in the treatment of hypertension. Angiology (2008) 0.84
Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study. Eur J Cardiovasc Prev Rehabil (2009) 0.84
The multivalent activity of the tissue factor-thrombin pathway in thrombotic and non-thrombotic disorders as a target for therapeutic intervention. Expert Opin Ther Targets (2010) 0.83
Stenting for renal-artery stenosis. N Engl J Med (2014) 0.82
The interaction of vasoactive substances during exercise modulates platelet aggregation in hypertension and coronary artery disease. BMC Cardiovasc Disord (2008) 0.82
National utilization of antihypertensive medications from 2000 to 2006 in the Veterans Health Administration: focus on thiazide diuretics. J Clin Hypertens (Greenwich) (2008) 0.82
Benefits from treatment and control of patients with resistant hypertension. Int J Hypertens (2010) 0.82
Hypertension and sexual dysfunction: time to act. J Hypertens (2011) 0.81
Heart rate at rest, exercise capacity, and mortality risk in veterans. Am J Cardiol (2013) 0.81
Prevalence, awareness, treatment and control of hypertension in an elderly population in Greece. Rural Remote Health (2010) 0.81
Renal nerve ablation for resistant hypertension: how did we get here, present status, and future directions. Circulation (2014) 0.81
Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study. Circulation (2002) 0.81
Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension Study. Hypertension (2006) 0.81
Relationship of ambulatory arterial stiffness index with blood pressure response to exercise in the early stages of hypertension. Blood Press Monit (2010) 0.81
Renal sympathetic denervation in hypertension. Curr Opin Nephrol Hypertens (2011) 0.80
Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial. Diabetes Care (2013) 0.80
Metabolic side effects and cardiovascular events of diuretics: should a diuretic remain the first choice therapy in hypertension treatment? The case of yes. Clin Exp Hypertens (2007) 0.80
Resistant hypertension: diagnosis and management. J Cardiovasc Pharmacol Ther (2006) 0.80
Aggressive blood pressure control and stroke prevention: role of calcium channel blockers. J Hypertens (2008) 0.80
A graded association of exercise capacity and all-cause mortality in males with high-normal blood pressure. Blood Press (2009) 0.79